• 1
    Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alfa is associated with dementia in centenarians. J Gerontol Med Sci 1999; 54A:M357 M364.
  • 2
    Paolisso G, Rizzo MR, Mazziotti G et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol Endocrin Metab 1998; 38:E294 E299.
  • 3
    Cohen HJ, Pieper CF, Harris T, Rao KK, Currie MS. The association of plasma IL-6 levels with functional disability in community dwelling elderly. J Gerontol Med Sci 1997; 52:M201 M208.
  • 4
    Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51:1953 6.
  • 5
    Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 1994; 15:771 2.
  • 6
    Ershler WB, Sun WH, Binkley N et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12:225 30.
  • 7
    Catania A, Airaghi L, Motta P et al. Cytokine antagonists in aged subjects and their relation with cellular immunity. J Gerontol Med Science 1997; 52:B93 B97.
  • 8
    Ballou SP, Lozanski FB, Hodder S et al. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 1996; 25:224 30.
  • 9
    Caswell M, Pike LA, Bull BS, Stuart J. Effect of patient age on tests of the acute-phase response. Arch Pathol Lab Med 1993; 117:906 10.
  • 10
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340:115 26.
  • 11
    Laman JD, De Smet BJGL, Schoneveld A, Van Meurs M. CD40–CD40L interactions in atherosclerosis. Immunol Today 1997; 18:272 7.
  • 12
    Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801 9.
  • 13
    Biasucci LM, Vitelli A, Liuzzo G et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94:874 7.
  • 14
    Biasucci LM, Liuzzo G, Fantuzzi G et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99:2079 84.
  • 15
    Harris TB, Ferrucci L, Tracy RP et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506 12.
  • 16
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973 9.
  • 17
    Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462 6.
  • 18
    Tracy RP, Lemaitre RN, Psaty BM et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17:1121 7.
  • 19
    Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312:1061 5.
  • 20
    Fowkes FG, Lowe GD, Housley E et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342:8863 6.
  • 21
    Meade TW, North WR, Chakrabarti R et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1:1050 4 .
  • 22
    Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88 92.
  • 23
    Belch JJ. The relationship between white blood cells and arterial disease. Curr Opin Lipidol 1994; 5:440 6.
  • 24
    Sharrett AR, Sorlie PD, Chambless LE et al. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 149:843 52.
  • 25
    Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980; 46:649 54.
  • 26
    Rose G & Shipley MJ. Plasma lipids and mortality: a source of error. Lancet 1980; 1:523 6.
  • 27
    Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981; 141:1128 31.
  • 28
    Yaari S, Goldbourt U, Even ZS, Neufeld HN. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men. Lancet 1981; 1:1011 5.
  • 29
    Richards C & Gauldie J. Role of cytokines in the acute-phase response. In: AggarwalBB, PuriRK, eds. Human cytokines: their roles in disease therapy. Cambridge, MA: Blackwell Science, 1995: 253 69.
  • 30
    Thorne SA, Abbot SE, Stevens CR, Winyard PG, Mills PG, Blake DR. Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells. Atherosclerosis 1996; 127:167 76.
  • 31
    Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999; 19:91 104.
  • 32
    Grunfeld C & Palladino MAJ. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med 1990; 35:45 71.
  • 33
    Feingold KR, Spady DK, Pollock AS, Moser AH, Grunfeld C. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res 1996; 37:223 8.
  • 34
    Feingold KR, Doerrler W, Dinarello CA, Fiers W, Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 1992; 130:10 16.
  • 35
    Fried SK & Zechner R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res 1989; 30:1917 23.
  • 36
    Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989; 124:2336 42.
  • 37
    Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353:1649 52 .
  • 38
    Schroll M, Jorgensen T, Ingerslev J. The Glostrup Population Studies, 1964–92. Dan Med Bull 1992; 39:204 7.
  • 39
    MONICA Manual, Part III. Population Survey. Geneva: WHO 1990.
  • 40
    Blann AD & McCollum CN. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation 1998; 22:483 91.
  • 41
    Uno H, Ueki Y, Murashima J et al. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans. Atherosclerosis 1995; 116:93 102.
  • 42
    Belmin J, Bernard C, Corman B, Merval R, Esposito B, Tedgui A. Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. Am J Physiol 1995; 268:H2288 H2293.
  • 43
    Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999; 83:515 8.
  • 44
    Madej A, Okopien B, Kowalski J et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998; 36:345 9.
  • 45
    Spriggs DR, Sherman ML, Michie H et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039 44.
  • 46
    Ettinger WHJ, Sun WH, Binkley N, Kouba E, Ershler W. Interleukin-6 causes hypocholesterolemia in middle-aged and old Rhesus monkeys. J Gerontol Med Scien 1995; 50:M137 M140.
  • 47
    Pajkrt D, Doran JE, Koster F et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601 8.
  • 48
    Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987 94.
  • 49
    Frostegard J, Huang YH, Ronnelid J, Schafer EL. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17:963 8.
  • 50
    Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 1996; 16:1573 9.
  • 51
    Jaattela M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 1991; 64:724 42.
  • 52
    Argiles JM, Lopez SJ, Busquets S, Lopez SF. Journey from cachexia to obesity by TNF. FASEB J 1997; 11:743 51.
  • 53
    Mooradian AD, Reed RL, Osterweil D, Clements N, Scuderi P. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. J Am Geriatr Soc 1990; 38:397 401.
  • 54
    Martinez M, Arnalich F, Hernanz A. Alterations of anorectic cytokine levels from plasma and cerebrospinal fluid in idiopathic senile anorexia. Mech Ageing Dev 1993; 72:145 53.